Evidence map›Paper›PMID 42686375›Full record

ArticleJournal for immunotherapy of cancer2026

GTPase RAB31 supports ANXA1-driven macrophage education through clathrin-mediated endocytosis to suppress antitumor immunity.

Jingjing Liu, Shanshan Wang, Dengyi Bao, Ge Dong, Yunxi Ma, Guorong Zhang, Xin Liu, Dongli Zhang, Lulu Wang, Shuqian Xu and 1 more

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jingjing LiuDepartment of Pharmacology, State Key Laboratory of Experimental Hematology, Tianjin Key Laboratory of Inflammatory Biology, School of Basic Medical Science, Tianjin Medical University, Tianjin, China US36zcai@tmu.edu.cn Liujingjing123@tmu.edu.cn shuqian.xu@email.sdu.edu.cn.ORCID http://orcid.org/0009-0009-2681-7936
Shanshan WangDepartment of Pharmacology, State Key Laboratory of Experimental Hematology, Tianjin Key Laboratory of Inflammatory Biology, School of Basic Medical Science, Tianjin Medical University, Tianjin, China.
Dengyi BaoDepartment of Bioinformatics, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Science, Tianjin Medical University, Tianjin, China.
Ge DongDepartment of Pharmacology, State Key Laboratory of Experimental Hematology, Tianjin Key Laboratory of Inflammatory Biology, School of Basic Medical Science, Tianjin Medical University, Tianjin, China.
Yunxi MaDepartment of Bioinformatics, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Science, Tianjin Medical University, Tianjin, China.
Guorong ZhangDepartment of Pharmacology, State Key Laboratory of Experimental Hematology, Tianjin Key Laboratory of Inflammatory Biology, School of Basic Medical Science, Tianjin Medical University, Tianjin, China.
Xin LiuDepartment of General Surgery, Tianjin Medical University General Hospital, Tianjin, China.ORCID http://orcid.org/0000-0003-3456-3795
Dongli ZhangSchool of Pharmacy, Tianjin Medical University, Tianjin, China.
Lulu WangSchool of Pharmacy, Tianjin Medical University, Tianjin, China.ORCID http://orcid.org/0000-0001-8402-5616
Shuqian XuShandong Provincial Clinical Research Center for Hematological Diseases, Shandong Key Laboratory of Hematological Diseases and Immune Microenvironment, Jinan, China US36zcai@tmu.edu.cn Liujingjing123@tmu.edu.cn shuqian.xu@email.sdu.edu.cn.
Zhigang CaiDepartment of Pharmacology, State Key Laboratory of Experimental Hematology, Tianjin Key Laboratory of Inflammatory Biology, School of Basic Medical Science, Tianjin Medical University, Tianjin, China US36zcai@tmu.edu.cn Liujingjing123@tmu.edu.cn shuqian.xu@email.sdu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor-associated macrophages (TAMs) play pivotal roles in shaping the tumor-microenvironment (TME) through functional plasticity, which is regulated by extrinsic and intrinsic signals. However, the role of vesicular trafficking in TAMs remains poorly understood. RAB31, a small GTPase enriched in myeloid cells, was proposed as a potential regulator of TAM polarization through clathrin-mediated endocytosis (CME). We hypothesized that RAB31 modulates TAM education by tumor-derived signals and thereby shapes antitumor immunity.

methodsWe profiled RAB31 expression in human cancers using public single-cell RNA sequencing (scRNA-seq) datasets and clinical sample immunofluorescence staining. Rab31 knockout mice were employed in subcutaneous tumor models. The TME was profiled by scRNA-seq, bulk RNA-seq, and flow cytometry. Bone marrow transplantation, adoptive cell transfer, and antibody-mediated depletion were performed to identify the effector cell populations. Co-immunoprecipitation coupled with mass spectrometry, receptor half-life assays, inhibitor intervention and lysosomal colocalization experiments dissected the molecular mechanism. Functional T-cell chemotaxis, activation, and anti-programmed death-ligand 1 (PD-L1) response assays were performed.

resultsRAB31 was highly expressed in TAMs across multiple cancers and correlated with poor prognosis and immunosuppressive TME. Rab31 deficiency reprogrammed TAMs to M1-like phenotype, enhanced CD8

conclusionsThese findings establish the CME/RAB31 pathway as an indispensable regulator of TAM polarization, underscoring the pivotal role of vesicular trafficking in the TME.

Indexed as

Annexin A1ClathrinEndocytosisMacrophagesNeoplasmsrab GTP-Binding ProteinsTumor-Associated MacrophagesAnimalsFemaleHumansMiceMice, KnockoutTumor MicroenvironmentAnnexin A1Clathrinrab GTP-Binding ProteinsBiomarkerImmunotherapyMacrophageTumor Microenvironment

Identifiers

PMID42686375
PMCPMC13548287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.